{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:40:02Z","timestamp":1723682402887},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7,21]]},"abstract":"<jats:sec>\n            <jats:title>Abstract:<\/jats:title>\n            <jats:p>There is no fee for this activity. To receive credit after reading this CME\/CE activity in its entirety, participants must complete the posttest and evaluation. The posttest and evaluation can be completed online at www.mlicme.org\/P17039.html.<\/jats:p>\n            <jats:p>Heart failure (HF) prevalence continues to rise and remains a significant burden to patients, caregivers, providers, and the healthcare system. Guideline-directed medical therapy with standard neurohormonal blockade has been the cornerstone of medical management for many years. Despite aggressive utilization of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists, HF hospitalizations and readmissions are common and residual mortality remains high. With the development of two novel medical therapies (sacubitril\/valsartan and ivabradine), the American College of Cardiology, American Heart Association, and Heart Failure Society of America released a pharmacologic update to provide guidelines for incorporation of these agents into clinical practice. Although effective via different mechanisms of action, both agents now have a prominent role in risk reduction. HF medical regimens often become quite complex, especially when associated with comorbid conditions, and require frequent follow-up. Providers must be proficient in patient monitoring, medication dose titration, and therapy optimization. Individualized patient care strategies such as guideline-directed therapy can promote long-term adherence and quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/01.npr.0000520610.88962.03","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T11:02:00Z","timestamp":1498129320000},"page":"3-14","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Improving heart failure patient outcomes utilizing guideline-directed therapy"],"prefix":"10.1097","volume":"42","author":[{"given":"Beth Towery","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri Lynn","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-2-20240814","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"R4-2-20240814","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R5-2-20240814","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ijcard.2012.11.065","article-title":"Worldwide risk factors for heart failure: a systematic review and pooled analysis","volume":"168","author":"Khatibzadeh","year":"2013","journal-title":"Int J Cardiol"},{"key":"R6-2-20240814","first-page":"e58","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"R12-2-20240814","first-page":"e282","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"R13-2-20240814","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"R14-2-20240814","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/S0024-3205(02)01990-2","article-title":"Increased expression of renal neutral endopeptidase in severe heart failure","volume":"71","author":"Knecht","year":"2002","journal-title":"Life Sci"},{"key":"R16-2-20240814","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"key":"R17-2-20240814","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"R18-2-20240814","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R20-2-20240814","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"R21-2-20240814","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"R22-2-20240814","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"R23-2-20240814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R25-2-20240814","first-page":"12","article-title":"Heart failure medications utilization and titration","volume":"51","author":"Glavao","year":"2017","journal-title":"The Connection: AAHFN Newsletter"},{"key":"R26-2-20240814","first-page":"11","article-title":"Tips for improving medication adherence.","volume":"9-","author":"Starr","year":"2017","journal-title":"Health monitor medical update on heart failure"},{"key":"R27-2-20240814","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","article-title":"Inotropes","volume":"63","author":"Francis","year":"2014","journal-title":"J Am College Cardiol"},{"key":"R28-2-20240814","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1573403X09666131117163825","article-title":"Advanced therapies for end-stage heart failure","volume":"11","author":"Katz","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"R30-2-20240814","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cardfail.2003.09.006","article-title":"Consensus statement: palliative and supportive care in advanced heart failure","volume":"10","author":"Goodlin","year":"2004","journal-title":"J Card Fail"},{"key":"R32-2-20240814","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cardfail.2008.10.005","article-title":"The heart failure clinic: a consensus statement of the Heart Failure Society of America","volume":"14","author":"Hauptman","year":"2008","journal-title":"J Card Fail"}],"container-title":["The Nurse Practitioner"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006205-201707001-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:07:29Z","timestamp":1723680449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006205-201707001-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":20,"journal-issue":{"issue":"Supplement 7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/01.npr.0000520610.88962.03","relation":{},"ISSN":["0361-1817"],"issn-type":[{"type":"print","value":"0361-1817"}],"subject":[],"published":{"date-parts":[[2017,7,21]]}}}